PsiThera

PsiThera is a pioneering biotechnology company dedicated to advancing innovative oral therapies for validated immunology targets that have long relied on injected biologics. Leveraging its state-of-the-art QUAISAR platform, PsiThera synthesizes advanced computational intelligence, integrating physics, machine learning, and structural biophysics to model dynamic protein behaviors. This approach allows them to predict and uncover hidden druggable states in proteins, facilitating the design of oral small molecules for challenging disease targets.

Currently, PsiThera's drug pipeline focuses on multiple targets within the tumor necrosis factor (TNF) superfamily and other areas, representing significant opportunities for creating the first oral treatments in these categories. Their breakthrough endeavors seek to deliver biologic-like efficacy without the need for injections, greatly enhancing patient accessibility and experience. Committed to redefining drug discovery, PsiThera combines cutting-edge technology with a dedicated team, poised to unlock new pathways for oral therapeutics in immunology and inflammation.